Christine S. Rizk, JD and Sanjiv N. Singh, MD, JD
Extending immunosuppressive drug coverage for the lifetime of kidney patients, instead of only covering dialysis, would be a cost-effective way for the federal government to reduce the costs of posttransplant care while improving clinical outcomes for patients.
Virtual Mentor. 2012; 14(3):250-255. doi:
10.1001/virtualmentor.2012.14.3.pfor3-1203.